Mayday for Dual PPAR Agonists

Once-Hyped Diabetes Therapies in Their Death Throes?
Emerging Technology


Metabolic Syndrome Pioglitazone Bezafibrate PPAR Agonist Avandia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294 (20): 2581–6PubMedCrossRefGoogle Scholar
  2. 2.
    Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29: 1016–23PubMedCrossRefGoogle Scholar
  3. 3.
    Nissen SE. Adverse events related to muraglitazar use in diabetes: reply. JAMA 2006; 295 (17): 1998CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Personalised recommendations